These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 9326913)

  • 1. Fecal occult blood screening in the Minnesota study: sensitivity of the screening test.
    Church TR; Ederer F; Mandel JS
    J Natl Cancer Inst; 1997 Oct; 89(19):1440-8. PubMed ID: 9326913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fecal occult blood screening in the Minnesota study: role of chance detection of lesions.
    Ederer F; Church TR; Mandel JS
    J Natl Cancer Inst; 1997 Oct; 89(19):1423-8. PubMed ID: 9326911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood.
    Mandel JS; Church TR; Ederer F; Bond JH
    J Natl Cancer Inst; 1999 Mar; 91(5):434-7. PubMed ID: 10070942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study.
    Mandel JS; Bond JH; Church TR; Snover DC; Bradley GM; Schuman LM; Ederer F
    N Engl J Med; 1993 May; 328(19):1365-71. PubMed ID: 8474513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interval cancers in a guaiac-based colorectal cancer screening programme: Consequences on sensitivity.
    Blom J; Törnberg S
    J Med Screen; 2017 Sep; 24(3):146-152. PubMed ID: 28142309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
    Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
    J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the sensitivity of fecal occult blood test screening for colorectal cancer.
    Lang CA; Ransohoff DF
    J Natl Cancer Inst; 1997 Oct; 89(19):1392-3. PubMed ID: 9326904
    [No Abstract]   [Full Text] [Related]  

  • 8. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of fecal occult-blood screening on the incidence of colorectal cancer.
    Mandel JS; Church TR; Bond JH; Ederer F; Geisser MS; Mongin SJ; Snover DC; Schuman LM
    N Engl J Med; 2000 Nov; 343(22):1603-7. PubMed ID: 11096167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy.
    Winawer SJ; Flehinger BJ; Schottenfeld D; Miller DG
    J Natl Cancer Inst; 1993 Aug; 85(16):1311-8. PubMed ID: 8340943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fecal occult blood screening for colorectal cancer. Is mortality reduced by chance selection for screening colonoscopy?
    Lang CA; Ransohoff DF
    JAMA; 1994 Apr; 271(13):1011-3. PubMed ID: 8139058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
    Smith A; Young GP; Cole SR; Bampton P
    Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fecal occult blood testing: clinical value and limitations.
    Simon JB
    Gastroenterologist; 1998 Mar; 6(1):66-78. PubMed ID: 9531118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population colorectal cancer screening with fecal occult blood test.
    Rennert G; Rennert HS; Miron E; Peterburg Y
    Cancer Epidemiol Biomarkers Prev; 2001 Nov; 10(11):1165-8. PubMed ID: 11700264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-invasive screening for colorectal cancer in Asia.
    Chiu HM; Chang LC; Hsu WF; Chou CK; Wu MS
    Best Pract Res Clin Gastroenterol; 2015 Dec; 29(6):953-65. PubMed ID: 26651256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity, specificity, and positive predictivity of the Hemoccult test in screening for colorectal cancers. The University of Minnesota's Colon Cancer Control Study.
    Mandel JS; Bond JH; Bradley M; Snover DC; Church TR; Williams S; Watt G; Schuman LM; Ederer F; Gilbertsen V
    Gastroenterology; 1989 Sep; 97(3):597-600. PubMed ID: 2666251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Men with negative results of guaiac-based fecal occult blood test have higher prevalences of colorectal neoplasms than women with positive results.
    Brenner H; Hoffmeister M; Birkner B; Stock C
    Int J Cancer; 2014 Jun; 134(12):2927-34. PubMed ID: 24374771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limitations of the faecal occult blood test in screening for colorectal cancer.
    Delcò F; Sonnenberg A
    Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):119-26. PubMed ID: 10363196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival of patients diagnosed with colorectal cancer through a television-advertised screening program.
    Slusser SO; Liberski SM; McGarrity TJ
    Am J Gastroenterol; 1996 Aug; 91(8):1563-6. PubMed ID: 8759662
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.